CoChat

The commercialization of genome-editing technologies

Brinegar, Katelyn, K. Yetisen, Ali, Choi, Sun, Vallillo, Emily, Ruiz-Esparza, Guillermo U., Prabhakar, Anand M., Khademhosseini, Ali, Yun, Seok-Hyun · 2017 · Critical Reviews in Biotechnology
Cited by 77

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/07388551.2016.1271768

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 31

  1. 10.1016/j.coviro.2015.03.011 · DOI
  2. Precision Biosciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology, Press Release, Cellectis. [cited 2016 Sep 22]. Available from: http://www.cellectis.com/en/content/precision-biosciences-and-cellectis-sa-announce-cross-license-and-settlement-agreement-gen-0.
  3. Cellectis and Thermo Fisher Scientific Enter into Agreements on Talen™, a Leading Gene Editing Technology, Press Release, Cellectis. [cited 2016 Sep 22]. Available from: http://www.cellectis.com/en/content/cellectis-and-thermo-fisher-scientific-enter-agreements-talentm-leading-gene-editing-0
  4. 10.1038/531149a · DOI
  5. 10.1038/532172a · doi:10.1038/532172a
  6. The data was compiled from press releases from the company websites, Keywords searched were “company name”, “gene editing technology”, and “license agreements” in Google. [cited 2016 Jan 15]. Available from: https://www.google.com/#q=Gene+Editing+Technology+License+Agreements
  7. Zhang F., 2014, CRISPR-Cas systems and methods for altering expression of gene products
  8. May AP, 2014, . WO2014150624 A1
  9. Le Buhan C., China. [cited 2016 May 25]. Available from:
  10. 10.1038/nbt.3590 · DOI
  11. 10.1016/j.irle.2009.06.001 · DOI
  12. 10.1038/nbt.3086 · DOI
  13. Sherkow JS., 2016, Biochemist e-volution, 38, 26, 10.1042/BIO03803026 · DOI
  14. 10.1172/JCI72992 · DOI · Paper page
  15. 10.1111/pbi.12444 · DOI · Paper page
  16. Fisher Scientific Completes Acquisition of Dharmacon; Expands Its Portfolio of Proprietary Products, Press Release, Thermofisher Scientific, Hampton, Nh. [cited 2016 May 25]. Available from: http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2004/Fisher-Scientific-Completes-Acquisition-of-Dharmacon-Expands-Its-Portfolio-of-Proprietary-Products/default.aspx
  17. Editas Medicine Raises $120 Million to Advance Genome Editing, Editas, Cambridge, MA. [cited 2016 May 25]. Available from: http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-newsArticle&ID=2125221
  18. Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology, Business Wire, Cambridge, MA. [cited 2016 May 25]. Available from: http://www.businesswire.com/news/home/20141118005077/en/Intellia-Therapeutics-Announces-15-Million-Funding-Develop
  19. Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases, Press Release, Bayer, Leverkusen, Germany and Basel, Switzerland. [cited 2016 May 25]. Available from: http://www.bayer.nl/nl/media/nieuws/bayer-and-crispr-therapeutics-ag-join-forces-to-discover-develop-and-commercialize-potential-cures-for-serious-genetic-diseases.php
  20. Baxalta and Precision Biosciences Form Global Genome Editing Collaboration in Immuno-Oncology, Press Release, Precision Biosciences, Durham, North Carolina. [cited 2016 May 25]. Available from: http://precisionbiosciences.com/baxalta-and-precision-biosciences-form-global-genome-editing-collaboration-in-immuno-oncology/
  21. 10.1038/nbt0609-531 · doi:10.1038/nbt0609-531
  22. 10.1038/nature.2016.19718 · DOI
  23. 10.1038/nature.2016.19754 · DOI · Paper page
  24. 10.2174/1566524016666160316150847 · doi:10.2174/1566524016666160316150847
  25. 10.1101/gr.162339.113 · DOI · Paper page
  26. 10.1093/nar/gku402 · DOI · Paper page
  27. 10.1038/nmeth.2857 · DOI · Paper page
  28. 10.1016/j.crvi.2003.09.017 · doi:10.1016/j.crvi.2003.09.017
  29. 10.1007/s10815-016-0753-x · doi:10.1007/s10815-016-0753-x
  30. 10.1038/nature.2015.17378 · DOI
  31. 10.1038/nature.2016.19270 · DOI

Cited by

See all 77

Metadata

Authors
Brinegar, K., K. Yetisen, A., Choi, S., Vallillo, E., Ruiz-Esparza, G. U., Prabhakar, A. M., Khademhosseini, A., & Yun, S.-H.
Affiliations
  • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA;
  • Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA;
  • Department of Radiology, Division of Cardiovascular Imaging, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA;
Venue
Critical Reviews in Biotechnology
Published
2017-01-18
Volume
37
Issue
7
Pages
924-932
ISSN
  • 0738-8551
  • 1549-7801
Cited by
77
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The commercialization of genome-editing technologies. https://app.cochat.ai/papers/10.1080/07388551.2016.1271768
The paper
Brinegar, K., K. Yetisen, A., Choi, S., Vallillo, E., Ruiz-Esparza, G. U., Prabhakar, A. M., Khademhosseini, A., & Yun, S.-H. (2017). The commercialization of genome-editing technologies. Critical Reviews in Biotechnology. https://doi.org/10.1080/07388551.2016.1271768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.